Latest News for: taras

Edit

Geno Auriemma breaks tie with Tara VanDerveer for most poll appearances by a coach as ...

The News-Enterprise 24 Feb 2026
Geno Auriemma breaks tie with Tara VanDerveer for most poll appearances by a coach as UConn remains No. 1 ... .
Edit

‘Firsts Are Special’: Tara Sutaria Gives Glimpse Of Her New Mumbai House

News18 24 Feb 2026
Tara Sutaria purchases her first home in Mumbai and shares housewarming photos. The actress calls the milestone special and embraces new beginnings in 2026 ....
Edit

Geno Auriemma’s 655th AP Top 25 appearance moves him past Tara VanDerveer

Weatherford Democrat 24 Feb 2026
Geno Auriemma broke a tie with Tara VanDerveer for most appearances by a coach in The Associated Press women’s basketball Top 25 on Monday when UConn was again a unanimous No. 1. Auriemma has the Huskies ranked for the 655th ....
Edit

Geno Auriemma's 655th AP Top 25 appearance moves him past Tara VanDerveer

Newsday 24 Feb 2026
Geno Auriemma broke a tie with Tara VanDerveer for most appearances by a coach in The Associated Press women's basketball Top 25 on Monday when UConn was again a unanimous No. 1. Auriemma has the Huskies ranked for the 655th time ... Credit ... No ... No ... ....
Edit

TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (Form 8-K) (Protara Therapeutics Inc)

Public Technologies 24 Feb 2026
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer ... We look forward to continuing to advance TARA-002's clinical development as we work to bring this treatment to patients.".
Edit

Why Ukraine’s use of drones isn’t the ‘future of war’ that you might imagine

The Scotsman 24 Feb 2026
Ukraine is using cheap drones not because they are the future of war, but because of a shortage of other munitions ....
Edit

TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Nasdaq Globe Newswire 23 Feb 2026
Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events ... .
×